Proteomics International Laboratories (PIQ) Q4 2025 TU earnings summary

Executive summary

• Completed $12 million capital raise to accelerate diagnostic test launches in Australia and the USA.

• PromarkerD test for diabetic kidney disease launched in the USA and Australia, with CPT PLA billing code granted.

• PromarkerEso and PromarkerEndo achieved key clinical milestones, with published validation and patent granted in Japan.

• OxiDx received a Chinese patent and published study results for muscle recovery monitoring.

• $6 million funding boost secured for WA Proteomics Facility to expand clinical testing capacity.

Financial highlights

• Cash receipts from customers for the June quarter were $201,000, up from $84,000 in the previous quarter.

• Net operating cash outflow for the June quarter was $3.2 million, compared to a $2.2 million inflow in the March quarter.

• Cash reserves at 30 June were $11.0 million, up from $3.1 million at 31 March, due to the capital raise.

• Forecast R&D tax incentive rebate of approximately $2 million expected in 1H FY25.

Outlook and guidance

• PromarkerD to expand rollout in the USA and Australia, leveraging digital direct-to-consumer platforms.

• PromarkerEso and PromarkerEndo commercial launches planned for H2 CY25 in Australia, with international expansion targeted.

• OxiDx test launch in Australia planned for H2 CY25, with US expansion to follow.

• Estimated 3.5 quarters of funding available at current cash burn, excluding the R&D rebate.